Prostate Cancer Survivorship Essentials for Men with Prostate Cancer on Androgen Deprivation Therapy: Protocol for a Randomised Controlled Trial of a Tele-based Nurse-led Survivorship Care Intervention (PCEssentials Hormone Therapy Study)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Mar 23

PMID 38521521

Authors

Anna Green

Robert U Newton

David P Smith

Haitham Tuffaha

Daniel A Galvao

Peter Heathcote

Manish I Patel

David Christie

Sam Egger

Sally Am Sara

Nicole Heneka

Suzanne K Chambers

Jeff Dunn

Affiliations

Soon will be listed here.

Abstract

Introduction: Androgen deprivation therapy (ADT) is commonly used to treat men with locally advanced or metastatic prostate cancer. Men receiving ADT experience numerous side effects and frequently report unmet supportive care needs. An essential part of quality cancer care is survivorship care. To date, an optimal effective approach to survivorship care for men with prostate cancer on ADT has not been described. This protocol describes a randomised trial of tele-based nurse-led survivorship that addresses this knowledge gap: (1) determine the effectiveness of a nurse-led survivorship care intervention (PCEssentials), relative to usual care, for improving health-related quality of life (HR-QoL) in men with prostate cancer undergoing ADT and (2) evaluate PCEssentials implementation strategies and outcomes, including cost-effectiveness, compared with usual care.

Methods And Analysis: This is an effectiveness-implementation hybrid (type 1) trial with participants randomised to one of two arms: (1) minimally enhanced usual care and (2) nurse-led prostate cancer survivorship essentials (PCEssentials) delivered over four tele-based sessions, with a booster session 5 months after session 1. Eligible participants are Australian men with prostate cancer commencing ADT and expected to be on ADT for a minimum of 12 months. Participants are followed up at 3, 6 and 12 months postrecruitment. Primary outcomes are HR-QoL and self-efficacy. Secondary outcomes are psychological distress, insomnia, fatigue and physical activity. A concurrent process evaluation with participants and study stakeholders will be undertaken to determine effectiveness of delivery of PCEssentials.

Ethics And Dissemination: Ethics approval was obtained from the Metro South Health HREC (HREC/2021/QMS/79429). All participants are required to provide written informed consent. Outcomes of this trial will be published in peer-reviewed journals. The findings will be presented at conferences and meetings, local hospital departments, participating organisations/clinical services, and university seminars, and communicated at community and consumer-led forums.

Trial Registration Number: ACTRN12622000025730.

Citing Articles

Effectiveness of educational and psychological survivorship interventions to improve health-related quality of life outcomes for men with prostate cancer on androgen deprivation therapy: a systematic review.

Sara S, Heneka N, Green A, Chambers S, Dunn J, Terry V BMJ Open. 2024; 14(5):e080310.

PMID: 38777593 PMC: 11116859. DOI: 10.1136/bmjopen-2023-080310.

References

Foster C, Breckons M, Cotterell P, Barbosa D, Calman L, Corner J . Cancer survivors' self-efficacy to self-manage in the year following primary treatment. J Cancer Surviv. 2014; 9(1):11-9. PMC: 4341005. DOI: 10.1007/s11764-014-0384-0. View

Kiosses D, Alexopoulos G . Problem-Solving Therapy in the Elderly. Curr Treat Options Psychiatry. 2014; 1(1):15-26. PMC: 3981073. DOI: 10.1007/s40501-013-0003-0. View

Hayes S, Newton R, Spence R, Galvao D . The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management. J Sci Med Sport. 2019; 22(11):1175-1199. DOI: 10.1016/j.jsams.2019.05.003. View

Rhee H, Gunter J, Heathcote P, Ho K, Stricker P, Corcoran N . Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2014; 115 Suppl 5:3-13. DOI: 10.1111/bju.12964. View

Chambers S, Ferguson M, Gardiner R, Nicol D, Gordon L, Occhipinti S . ProsCan for men: randomised controlled trial of a decision support intervention for men with localised prostate cancer. BMC Cancer. 2008; 8:207. PMC: 2515322. DOI: 10.1186/1471-2407-8-207. View

Chambers S, Hyde M, Smith D, Hughes S, Yuill S, Egger S . New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. Psychooncology. 2017; 26(7):873-913. PMC: 5535006. DOI: 10.1002/pon.4431. View

Mazariego C, Egger S, King M, Juraskova I, Woo H, Berry M . Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ. 2020; 371:m3503. PMC: 7539021. DOI: 10.1136/bmj.m3503. View

Galvao D, Taaffe D, Hayne D, Lopez P, Lyons-Wall P, Tang C . Weight loss for overweight and obese patients with prostate cancer: a study protocol of a randomised trial comparing clinic-based versus Telehealth delivered EXercise and nutrition intervention (the TelEX trial). BMJ Open. 2022; 12(6):e058899. PMC: 9171278. DOI: 10.1136/bmjopen-2021-058899. View

Dunn J, Green A, Ralph N, Newton R, Kneebone A, Frydenberg M . Prostate cancer survivorship essentials framework: guidelines for practitioners. BJU Int. 2020; 128 Suppl 3:18-29. PMC: 9291032. DOI: 10.1111/bju.15159. View

10.

Zajdlewicz L, Hyde M, Lepore S, Gardiner R, Chambers S . Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study. Cancer Nurs. 2017; 40(5):412-419. DOI: 10.1097/NCC.0000000000000432. View

11.

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A . Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2010; 38(2):65-76. PMC: 3068522. DOI: 10.1007/s10488-010-0319-7. View

12.

Bellg A, Borrelli B, Resnick B, Hecht J, Minicucci D, Ory M . Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychol. 2004; 23(5):443-51. DOI: 10.1037/0278-6133.23.5.443. View

13.

Edmunds K, Tuffaha H, Galvao D, Scuffham P, Newton R . Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer. 2020; 28(5):2079-2093. DOI: 10.1007/s00520-019-05255-5. View

14.

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

15.

Smith D, King M, Egger S, Berry M, Stricker P, Cozzi P . Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009; 339:b4817. PMC: 2784818. DOI: 10.1136/bmj.b4817. View

16.

Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P . Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013; 49(7):1588-99. PMC: 5489254. DOI: 10.1016/j.ejca.2012.12.018. View

17.

Gray R, Wassersug R, Sinding C, Barbara A, Trosztmer C, Fleshner N . The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study. Can J Urol. 2005; 12(4):2755-63. View

18.

Faller H, Schuler M, Richard M, Heckl U, Weis J, Kuffner R . Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013; 31(6):782-93. DOI: 10.1200/JCO.2011.40.8922. View

19.

Chipperfield K, Fletcher J, Millar J, Brooker J, Smith R, Frydenberg M . Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psychooncology. 2013; 22(10):2169-76. DOI: 10.1002/pon.3269. View

20.

Weiner B, Lewis C, Stanick C, Powell B, Dorsey C, Clary A . Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017; 12(1):108. PMC: 5576104. DOI: 10.1186/s13012-017-0635-3. View